← Back to Search

Neuropeptide

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

Phase 1
Waitlist Available
Led By Etienne Sochett, MD
Research Sponsored by Vanilloid Genetics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 and 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if delivering a natural body chemical called substance P to a major artery can help people recently diagnosed with type 1 diabetes. The goal is to reduce inflammation and support the pancreas in managing blood sugar levels better.

Eligible Conditions
  • Diabetes
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Stage A Safety: Side effects reported for entire cohort
Secondary study objectives
C-Peptide Levels (large cohort)
C-Peptide Levels (small cohort)
Other study objectives
sP Longevity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Substance P - 5nmol/kgExperimental Treatment1 Intervention
Substance P 5nmol/kg intra-celiac artery, single treatment
Group II: Substance P - 45nmol/kgExperimental Treatment1 Intervention
Substance P 45nmol/kg intra-celiac artery, single treatment
Group III: Substance P - 1nmol/kgExperimental Treatment1 Intervention
Substance P 1nmol/kg intra-celiac artery, single treatment
Group IV: Substance P - 15nmol/kgExperimental Treatment1 Intervention
Substance P 15nmol/kg intra-celiac artery, single treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Substance P
2021
N/A
~40

Find a Location

Who is running the clinical trial?

Vanilloid Genetics Inc.Lead Sponsor
Etienne Sochett, MDPrincipal InvestigatorHospital for Sick Children, Toronto Ontario
2 Previous Clinical Trials
26 Total Patients Enrolled
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top